Table 2.
Changes in WHO FC, NT-proBNP, 6MWD, hemodynamics, and volumetric MRI parameters at 36 weeks of therapy compared to baseline.
| Parameter | Baseline | Follow-up | Change | P value |
|---|---|---|---|---|
| WHO FC (I/II/III/IV) | 0/8/13/0 | 1/11/9/0 | ||
| 6MWD (m) | 390 (260–438) | 428 (311–468) | 44 (–3 – 76) | 0.003 |
| NT-proBNP (pg/mL) | 426 (140–1517) | 329 (93–655) | –44 (–909 – 69) | 0.053 |
| RAP (mmHg) | 6 (4–11) | 5 (3–8) | –2 (–6 – 2) | 0.11 |
| mPAP (mmHg) | 37 (33–46) | 30 (24–36) | –9 (–12 – –6) | <0.0001 |
| CI (L/min/m2) | 2.5 (2.2–3) | 3.2 (2.6–3.8) | 0.6 (–0.2 – 1.1) | 0.0085 |
| Stroke volume index (mL/m2) | 33 (28–42) | 45 (37–54) | 10 (1–16) | 0.0005 |
| PAWP (mmHg) | 9 (6–12) | 11 (8–14) | 1 (–3 – 6) | 0.25 |
| PVR (Wood units) | 6.8 (4–11) | 3 (2–5.6) | –3.8 (–5.4 – 1.5) | < 0.0001 |
| RVEF (%) | 47 (42–54) | 56 (53–64) | 3 (–4 – 9) | < 0.0001 |
| RVED volume (mL) | 151 (139–172) | 160 (129–166) | 0 (–20 – 7) | 0.65 |
| RVES volume (mL) | 80 (62–94) | 58 (82–49) | –12 (–30 – –3) | 0.003 |
| RV mass (g) | 28 (23–39) | 28 (20–34) | –3 (–9 – 1) | 0.06 |
| LVEF (%) | 64 (60–68) | 63 (59–68) | 1 (–6 – 4) | 0.88 |
| LVED volume (mL) | 115 (91–137) | 136 (119–161) | 19 (11–40) | < 0.0001 |
| LVES volume (mL) | 39 (31–52) | 50 (40–61) | 7 (1–17) | 0.004 |
| LV mass (g) | 88 (72–107) | 97 (75–109) | 7 (–6 – 14) | 0.15 |
Data represent median (IQR) (n = 21 for each parameter).
6MWD, 6-min walk distance; NT-proBNP, N-Terminal pro-brain natriuretic peptide; mPAP, mean pulmonary arterial pressure; RAP, right atrial pressure; CI, cardiac index; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RV, right ventricular; EF, ejection fraction; ED, endo diastolic; ES, endo systolic; LV, left ventricular; RVED, right ventricle end-diastolic; RVED vol, RVED volume; RVES, RV end-systolic volume; LVED vol, left ventricle end-diastolic volume; LVES vol, LV end-systolic volume.